International Agency for Research on Cancer, World Health Organization
Johansson, Mattias (författare)
International Agency for Research on Cancer, World Health Organization
Boeing, Heiner (författare)
German Institute of Human Nutrition
Trichopoulou, Antonia (författare)
National and Kapodistrian University of Athens
Benetou, Vassiliki (författare)
National and Kapodistrian University of Athens
La Vecchia, Carlo (författare)
University of Milan
Sieri, Sabina (författare)
Istituto Nazionale dei Tumori
Mattiello, Amalia(författare)
Palli, Domenico(författare)
Tumino, Rosario(författare)
Matullo, Giuseppe (författare)
Citta' della Salute e della Scienza Hospital-University of Turin
Onland-Moret, N. Charlotte (författare)
University Medical Center Utrecht
Gram, Inger T. (författare)
UiT The Arctic University of Norway, Tromsø
Weiderpass, Elisabete (författare)
Folkhälsan Research Center
Sánchez, Maria Jose(författare)
Navarro Sanchez, Carmen (författare)
Murcia Regional Health Council
Duell, Eric J. (författare)
Catalan Institute of Oncology
Ardanaz, Eva (författare)
CIBERONC Centro de Investigación Biomédica en Red Cáncer
Larranaga, Nerea(författare)
Lundin, Eva(författare)
Idahl, Annika (författare)
Umeå University
Jirström, Karin (författare)
Lund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Personlig patologi och cancerbehandling,Forskargrupper vid Lunds universitet,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Personalized Pathology & Cancer Therapy,Lund University Research Groups,Skåne University Hospital
Nodin, Björn (författare)
Lund University,Lunds universitet,Personlig patologi och cancerbehandling,Forskargrupper vid Lunds universitet,Personalized Pathology & Cancer Therapy,Lund University Research Groups,Skåne University Hospital
Immuno-proteomic screening has identified several tumor-associated autoantibodies (AAb) that may have diagnostic capacity for invasive epithelial ovarian cancer, with AAbs to P53 proteins and cancer-testis antigens (CTAGs) as prominent examples. However, the early detection potential of these AAbs has been insufficiently explored in prospective studies. We performed ELISA measurements of AAbs to CTAG1A, CTAG2, P53 and NUDT11 proteins, for 194 patients with ovarian cancer and 705 matched controls from the European EPIC cohort, using serum samples collected up to 36 months prior to diagnosis under usual care. CA125 was measured using electrochemo-luminiscence. Diagnostic discrimination statistics were calculated by strata of lead-time between blood collection and diagnosis. With lead times ≤6 months, ovarian cancer detection sensitivity at 0.98 specificity (SE98) varied from 0.19 [95% CI 0.08-0.40] for CTAG1A, CTAG2 and NUDT1 to 0.23 [0.10-0.44] for P53 (0.33 [0.11-0.68] for high-grade serous tumors). However, at longer lead-times, the ability of these AAb markers to distinguish future ovarian cancer cases from controls declined rapidly; at lead times >1 year, SE98 estimates were close to zero (all invasive cases, range: 0.01-0.11). Compared to CA125 alone, combined logistic regression scores of AAbs and CA125 did not improve detection sensitivity at equal level of specificity. The added value of these selected AAbs as markers for ovarian cancer beyond CA125 for early detection is therefore limited.
Ämnesord
MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin (hsv//swe)
MEDICAL AND HEALTH SCIENCES -- Clinical Medicine (hsv//eng)